secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2021-08-13T23:59:59+00:00
Accession:  0001193125-21-244963
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Therapeutics appoints William Guyer as CDO; CMO Andreas Grauer departs
------------------------------------------------------------------------------

- Andreas Grauer separated as CMO effective Aug 10, 2021, becomes senior medical advisor to assist transition.
- William Guyer, formerly SVP at Gilead Sciences, appointed CDO effective Aug 16, 2021.
- Guyer brings ~30 years of experience; led global Medical Affairs at Gilead, involved in multiple drug launches.
- Separation agreement provides Grauer one-year salary continuation, COBRA coverage, and quarterly housing allowance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/0001193125-21-244963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312521244963/d552481d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-244963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer